
COMPETE Clinical Trial
A new phase III clinical trial called COMPETE (NCT03049189 ) compares everolimus, an oral targeted therapy, to PRRT with Lu-177 edotreotide, a radiopharmaceutical under development,
Announcing the launch of Breakthroughs Today, Cures Tomorrow, our 20th anniversary campaign!
A new phase III clinical trial called COMPETE (NCT03049189 ) compares everolimus, an oral targeted therapy, to PRRT with Lu-177 edotreotide, a radiopharmaceutical under development,
Following the loss of a loved one, holiday traditions may be more painful than joyful. Many things can trigger memories that seem to amplify your
Approximately 20% of all primary lung tumors are neuroendocrine (Hung 2019), including: Typical carcinoid (TC) Atypical carcinoid (AC) Small cell carcinoma (SCC) Large cell carcinoma
The late Carl Schaad captured on canvas the beauty of New England and Italy, with expansive landscapes and small still life. Family and friends gathered
Highlights from NANETS 2019 symposium where leading NET experts presented progress and identified priorities for moving NET knowledge and care forward.
Living with cancer increases your risk for complications from influenza (“flu”). If you have cancer now, have had cancer in the past, or live with
Almost 2 years after his NET diagnosis, Maros Felsen organizes and runs a 5K neuroendocrine cancer fundraiser. He’s proof for all that you can lead an active, meaningful, and successful life with neuroendocrine cancer.
Vicki Dailey organizes an annual two-state, 82-mile bikeride to honor her sister’s experience with neuroendocrine cancer to move us closer to a cure.
A small town in Maine finds its zebra stripes after two first responders and a town official succumbed to NETs since 2017. See how they are raising awareness and money for research.
Dr. Elizabeth Zide vs. Neuroendocrine Cancer Members “Nothing But NET” marathon relay team. (left to right) Elizabeth Zide, Alaina Kronenberg, and Cassi Cohen. Her lifestyle